COVID‐19 Hospitalization Outcomes Among Patients With Autoimmune Rheumatic Diseases in the United States
Objectives To investigate the outcomes of COVID‐19‐related hospitalizations among patients with autoimmune rheumatic diseases (ARDs) in the United States in 2020. The primary outcome was in‐hospital mortality, and secondary outcomes included intubation rate, length of hospital stay (LOS), and total...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-07-01
|
| Series: | ACR Open Rheumatology |
| Online Access: | https://doi.org/10.1002/acr2.11572 |
| _version_ | 1797658204545482752 |
|---|---|
| author | Ahmad Khalaf Garad Ibrahim Spencer Goble Marcela Kuijpers Rawad Nasr |
| author_facet | Ahmad Khalaf Garad Ibrahim Spencer Goble Marcela Kuijpers Rawad Nasr |
| author_sort | Ahmad Khalaf |
| collection | DOAJ |
| description | Objectives To investigate the outcomes of COVID‐19‐related hospitalizations among patients with autoimmune rheumatic diseases (ARDs) in the United States in 2020. The primary outcome was in‐hospital mortality, and secondary outcomes included intubation rate, length of hospital stay (LOS), and total hospital charges (THCs). Methods Data for the study were obtained from the National Inpatient Sample database and included patients who were hospitalized with a principal diagnosis of COVID‐19. Univariable and multivariable logistic regression analyses were conducted to calculate odds ratios for the outcomes, adjusting for age, sex, and comorbidities. Results Out of the 1,050,720 COVID‐19 admissions, 30,775 had an ARD diagnosis. The unadjusted analysis showed higher mortality (12.21%) and intubation (9.2%) rates in the ARD group compared with the non‐ARD group (mortality rate: 11.14%, P = 0.013; intubation rate: 8.5%, P = 0.048). However, this difference was not significant after adjusting for confounding factors. The mean LOS and THCs did not differ significantly between the two groups. Among all ARD subgroups, the vasculitis group had significantly higher intubation rate, LOS, and THC. Conclusion The study suggests that ARD is not associated with an increased risk of mortality or worse outcomes among patients hospitalized with COVID‐19 after adjusting for confounding factors. However, the vasculitis group had poorer outcomes during COVID‐19 hospitalizations. Further studies are needed to evaluate the effect of ARD activity and immunosuppressants on outcomes. Additionally, more research is required to investigate the relationship between COVID‐19 and vasculitis. |
| first_indexed | 2024-03-11T17:55:49Z |
| format | Article |
| id | doaj.art-21d1db85bc9c4325aeeeba0bdbb33161 |
| institution | Directory Open Access Journal |
| issn | 2578-5745 |
| language | English |
| last_indexed | 2024-03-11T17:55:49Z |
| publishDate | 2023-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | ACR Open Rheumatology |
| spelling | doaj.art-21d1db85bc9c4325aeeeba0bdbb331612023-10-17T12:40:48ZengWileyACR Open Rheumatology2578-57452023-07-015736437010.1002/acr2.11572COVID‐19 Hospitalization Outcomes Among Patients With Autoimmune Rheumatic Diseases in the United StatesAhmad Khalaf0Garad Ibrahim1Spencer Goble2Marcela Kuijpers3Rawad Nasr4Hennepin County Medical Center Minneapolis MinnesotaHennepin County Medical Center Minneapolis MinnesotaHennepin County Medical Center Minneapolis MinnesotaHennepin County Medical Center Minneapolis MinnesotaHennepin County Medical Center Minneapolis MinnesotaObjectives To investigate the outcomes of COVID‐19‐related hospitalizations among patients with autoimmune rheumatic diseases (ARDs) in the United States in 2020. The primary outcome was in‐hospital mortality, and secondary outcomes included intubation rate, length of hospital stay (LOS), and total hospital charges (THCs). Methods Data for the study were obtained from the National Inpatient Sample database and included patients who were hospitalized with a principal diagnosis of COVID‐19. Univariable and multivariable logistic regression analyses were conducted to calculate odds ratios for the outcomes, adjusting for age, sex, and comorbidities. Results Out of the 1,050,720 COVID‐19 admissions, 30,775 had an ARD diagnosis. The unadjusted analysis showed higher mortality (12.21%) and intubation (9.2%) rates in the ARD group compared with the non‐ARD group (mortality rate: 11.14%, P = 0.013; intubation rate: 8.5%, P = 0.048). However, this difference was not significant after adjusting for confounding factors. The mean LOS and THCs did not differ significantly between the two groups. Among all ARD subgroups, the vasculitis group had significantly higher intubation rate, LOS, and THC. Conclusion The study suggests that ARD is not associated with an increased risk of mortality or worse outcomes among patients hospitalized with COVID‐19 after adjusting for confounding factors. However, the vasculitis group had poorer outcomes during COVID‐19 hospitalizations. Further studies are needed to evaluate the effect of ARD activity and immunosuppressants on outcomes. Additionally, more research is required to investigate the relationship between COVID‐19 and vasculitis.https://doi.org/10.1002/acr2.11572 |
| spellingShingle | Ahmad Khalaf Garad Ibrahim Spencer Goble Marcela Kuijpers Rawad Nasr COVID‐19 Hospitalization Outcomes Among Patients With Autoimmune Rheumatic Diseases in the United States ACR Open Rheumatology |
| title | COVID‐19 Hospitalization Outcomes Among Patients With Autoimmune Rheumatic Diseases in the United States |
| title_full | COVID‐19 Hospitalization Outcomes Among Patients With Autoimmune Rheumatic Diseases in the United States |
| title_fullStr | COVID‐19 Hospitalization Outcomes Among Patients With Autoimmune Rheumatic Diseases in the United States |
| title_full_unstemmed | COVID‐19 Hospitalization Outcomes Among Patients With Autoimmune Rheumatic Diseases in the United States |
| title_short | COVID‐19 Hospitalization Outcomes Among Patients With Autoimmune Rheumatic Diseases in the United States |
| title_sort | covid 19 hospitalization outcomes among patients with autoimmune rheumatic diseases in the united states |
| url | https://doi.org/10.1002/acr2.11572 |
| work_keys_str_mv | AT ahmadkhalaf covid19hospitalizationoutcomesamongpatientswithautoimmunerheumaticdiseasesintheunitedstates AT garadibrahim covid19hospitalizationoutcomesamongpatientswithautoimmunerheumaticdiseasesintheunitedstates AT spencergoble covid19hospitalizationoutcomesamongpatientswithautoimmunerheumaticdiseasesintheunitedstates AT marcelakuijpers covid19hospitalizationoutcomesamongpatientswithautoimmunerheumaticdiseasesintheunitedstates AT rawadnasr covid19hospitalizationoutcomesamongpatientswithautoimmunerheumaticdiseasesintheunitedstates |